IMAC vs. BEAT, CERS, MGTX, ANRO, LFMD, TNYA, SBTX, NAUT, SOPH, and ZYXI
Should you be buying IMAC stock or one of its competitors? The main competitors of IMAC include BioTelemetry (BEAT), Cerus (CERS), MeiraGTx (MGTX), Alto Neuroscience (ANRO), LifeMD (LFMD), Tenaya Therapeutics (TNYA), Silverback Therapeutics (SBTX), Nautilus Biotechnology (NAUT), SOPHiA GENETICS (SOPH), and Zynex (ZYXI). These companies are all part of the "medical" sector.
IMAC (NASDAQ:IMAC) and BioTelemetry (NASDAQ:BEAT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership.
BioTelemetry has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat BioTelemetry's return on equity.
BioTelemetry has a consensus price target of $8.00, indicating a potential upside of 172.11%. Given BioTelemetry's higher probable upside, analysts clearly believe BioTelemetry is more favorable than IMAC.
24.3% of IMAC shares are held by institutional investors. Comparatively, 7.8% of BioTelemetry shares are held by institutional investors. 10.0% of IMAC shares are held by company insiders. Comparatively, 20.9% of BioTelemetry shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
IMAC has higher revenue and earnings than BioTelemetry.
In the previous week, IMAC had 5 more articles in the media than BioTelemetry. MarketBeat recorded 8 mentions for IMAC and 3 mentions for BioTelemetry. IMAC's average media sentiment score of 0.49 beat BioTelemetry's score of 0.00 indicating that IMAC is being referred to more favorably in the media.
BioTelemetry received 318 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 63.77% of users gave BioTelemetry an outperform vote while only 60.17% of users gave IMAC an outperform vote.
IMAC has a beta of -0.88, meaning that its stock price is 188% less volatile than the S&P 500. Comparatively, BioTelemetry has a beta of -1.12, meaning that its stock price is 212% less volatile than the S&P 500.
Summary
IMAC beats BioTelemetry on 8 of the 14 factors compared between the two stocks.
Get IMAC News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
